Two Sigma Securities’s LAVA Therapeutics LVTX Stock Holding History

Two Sigma Securities’s Portfolio LVTX Stock Details LVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-14,236	Closed	-$18.8K	–	1763
2025 Q2	$18.8K	Buy	+14,236	New	+$18.1K	﹤0.01%	1220
2025 Q1	–	Sell	-13,157	Closed	-$12.5K	–	1894
2024 Q4	$12.5K	Buy	+13,157	New	+$20.7K	﹤0.01%	1405
2024 Q2	–	Sell	-12,908	Closed	-$43K	–	3377
2024 Q1	$43K	Buy	+12,908	New	+$28.4K	﹤0.01%	2586

Other funds holding LVTX

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Two Sigma Securities's LVTX Position: Q3 2025 in Review

Two Sigma Securities sold out of LAVA Therapeutics (LVTX) in Q3 2025, closing a stake of 14,236 shares — an estimated $18.8K sold.

Two Sigma Securities first reported a position in LVTX in Q1 2024 and held it in 3 quarters. The position peaked at $43K in Q1 2024. 21 funds tracked by Wall St. Rank hold LVTX as of Q3 2025.

Two Sigma Securities reported no remaining LAVA Therapeutics position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 14,236 LAVA Therapeutics shares in Q3 2025, an estimated $18.8K.
Two Sigma Securities first reported a position in LAVA Therapeutics in Q1 2024 and held it in 3 quarters.
Two Sigma Securities's LAVA Therapeutics position peaked at $43K in Q1 2024.
21 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.